Science Daily - Stroke
SEPTEMBER 1, 2024
Wearable, long-term continuous heart monitors helped identify 52% more cases of atrial fibrillation compared to usual care, but that did not lead to a reduction in hospitalizations due to stroke, according to a new study.
Heart Sisters
SEPTEMBER 1, 2024
After my book was published, the hospital that had sent me home in mid-heart attack with an acid reflux misdiagnosis invited me to be the guest speaker at a fundraising campaign they were about to launch.
JAMA Cardiology
SEPTEMBER 1, 2024
This post hoc analysis of a randomized clinical trial analyzes imaging data for atheroma volume at the lesion level from patients who received intensive lipid-lowering therapy with alirocumab plus statin compared with a statin alone.
Med Page Today
SEPTEMBER 1, 2024
(MedPage Today) -- LONDON -- Some individuals already undergoing transcatheter aortic valve replacement (TAVR, also TAVI) might as well get coronary lesions revascularized around the same time, according to the NOTION-3 randomized trial. Clinical.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
HeartRhythm
SEPTEMBER 1, 2024
Left bundle branch pacing (LBBP) is a novel physiological pacing modality. However, whether it delivers comparable efficacy with different capture sites in heart failure (HF) patients remains unclear.
JAMA Cardiology
SEPTEMBER 1, 2024
After the introduction of statins in 1987 and the publication of the landmark Scandinavian Simvastatin Survival Trial in 1996, extraordinarily robust evidence has accumulated demonstrating that lowering levels of low-density lipoprotein cholesterol (LDL-C) is associated with a major reduction in cardiovascular morbidity and mortality. Determining how the reduction in LDL-C results in these benefits has been the subject of intense scientific interest during the last 4 decades.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
The New England Journal of Medicine
SEPTEMBER 1, 2024
In this phase 3 trial involving patients with persistant chylomicronemia, plozasiran, a short interfering RNA that targets APOC3, reduced triglyceride levels and the incidence of pancreatitis.
HCPLive
SEPTEMBER 1, 2024
FINEARTS-HF results suggest finerenone may join SGLT2 inhibitors as a second pillar in treating HFmrEF/HFpEF, cutting total heart failure events by 16%.
JAMA Cardiology
SEPTEMBER 1, 2024
This essay describes concerns that use of artificial intelligence (AI) as a replacement rather than a supplement in the provision of medical care may lead to loss of the art of medicine and the collaborative partnership between physician and patient.
HCPLive
SEPTEMBER 1, 2024
Asundexian failed to prove noninferiority to apixaban for its primary efficacy outcome in the phase 3 OCEANIC-AF trial.
American College of Cardiology
SEPTEMBER 1, 2024
Fasting prior to cath lab procedures requiring conscious sedation may not be needed, based on findings from the SCOFF trial presented at ESC Congress 2024 in London.
HCPLive
SEPTEMBER 1, 2024
Matthew Cavender, MD, MPH, discusses a study he led at ESC Congress examining utility of the SCORE2-Diabetes risk score using clinical trial data.
American College of Cardiology
SEPTEMBER 1, 2024
The following are key points to remember from the 2024 European Society of Cardiology (ESC) guidelines for the management of chronic coronary syndromes (CCS).
HCPLive
SEPTEMBER 1, 2024
MAVA-LTE trial data show mavacamten's sustained benefits in symptomatic obstructive HCM, with long-term improvements in LVOT, NT-proBNP, and quality of life.
American College of Cardiology
SEPTEMBER 1, 2024
In patients with high-risk atrial fibrillation (AFib) and stable coronary artery disease, endoxaban monotherapy when given as a long-term antithrombotic therapy was associated with better net clinical benefit than edoxaban plus a single antiplatelet agent, based on findings from the EPIC-CAD trial presented at ESC Congress 2024 in London and simultaneously published in The New England Journal of Medicine (NEJM).
Dr. Smith's ECG Blog
SEPTEMBER 1, 2024
Abstract of QOH Retrospective Data by Willy Frick MD et al.
Journal of Cardiothoracic Surgery
SEPTEMBER 1, 2024
Mycoplasma pneumoniae pneumonia (MPP) is responsible for 20 to 40% of all cases of pneumonia acquired by children and shows an increasing incidence year by year. The aim of this study was to investigate the ex.
Med Page Today
SEPTEMBER 1, 2024
(MedPage Today) -- LONDON -- The nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone (Kerendia) improved outcomes driven by soft endpoints in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF.
Journal of Cardiothoracic Surgery
SEPTEMBER 1, 2024
To investigate the protective effect and mechanism of Ghrelin on Doxorubicin (Dox) hydrochloride induced heart failure (HF) and myocardial injury in rats.
Med Page Today
SEPTEMBER 1, 2024
(MedPage Today) -- LONDON -- For patients with atrial fibrillation (Afib) and stable coronary artery disease (CAD), edoxaban (Savaysa) monotherapy improved net outcomes weighing together bleeding and ischemic events as compared with dual antithrombotic.
Journal of Cardiothoracic Surgery
SEPTEMBER 1, 2024
Streptococcus pneumoniae (Spn) is a major causative agent of pneumonia, which can disseminate to the bloodstream and brain. Pneumonia remains a leading cause of death among children aged 1–59 months worldwide. Th.
Dr. S. Venkatesan MD
SEPTEMBER 1, 2024
CAPTIM trial was published in 2002, which left a gospel truth in the science of myocardial reperfusion (two decades gone now). It is a sad academic story ,most of the interventional cardiology community shrugged it off as a non-event. After CAPTIM , there were several other studies that tried to reiterate the same. The fact of the matter is, in the art and science of reperfusion, all that glitters may not be gold at the myocardium level.
American College of Cardiology
SEPTEMBER 1, 2024
An invasive treatment strategy involving coronary angiography and revascularization plus medical therapy did not significantly lower the composite risk of cardiovascular death or nonfatal myocardial infarction (MI) compared with a conservative strategy of medical therapy alone in older adults with NSTEMI, according to findings from the SENIOR-RITA trial presented at ESC Congress 2024 in London and simultaneously published in The New England Journal of Medicine.
The New England Journal of Medicine
SEPTEMBER 1, 2024
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 European Society of Cardiology annual meeting.
American College of Cardiology
SEPTEMBER 1, 2024
The goal of the OCEANIC-AF trial was to determine whether asundexian, a direct and selective factor XIa inhibitor, is 1) noninferior in preventing stroke or systemic thromboembolism, and 2) superior with respect to major bleeding risk compared with apixaban in patients with atrial fibrillation (AF) requiring oral anticoagulant therapy.
Clinical Trial Results
SEPTEMBER 1, 2024
Lopes Download Disclosures: TBD
American College of Cardiology
SEPTEMBER 1, 2024
The goal of the EPIC-CAD trial was to evaluate edoxaban monotherapy compared with edoxaban/antiplatelet therapy among patients with atrial fibrillation (AF) and chronic coronary disease.
Clinical Trial Results
SEPTEMBER 1, 2024
Disclosures: TBD
American College of Cardiology
SEPTEMBER 1, 2024
Village doctors in rural China trained to manage the care of older adults with atrial fibrillation (AFib) and supported by AFib experts in tertiary hospitals through telemedicine lowered the risk of AFib-related adverse cardiovascular events by 36% over three years, based on findings from the MIRACLE-AF trial presented at ESC Congress 2024 in London.
Clinical Trial Results
SEPTEMBER 1, 2024
Copy of Campo_Gianluca Download Disclosures: TBD
American College of Cardiology
SEPTEMBER 1, 2024
The goal of the SENIOR-RITA trial was to evaluate routine invasive therapy compared with conservative therapy among older patients with non–ST-elevation myocardial infarction (NSTEMI).
Clinical Trial Results
SEPTEMBER 1, 2024
Copy of Ferreira_David SCOFF ESC 2024 Download Disclosures: TBD
American College of Cardiology
SEPTEMBER 1, 2024
A short educational program for targeted at health care professionals in France, Germany, Italy, Poland, Spain and the UK increased patient-level adherence to guideline recommendations on atrial fibrillation (AFib) management, based on findings from the STEEER-AF trial presented at ESC Congress 2024 in London.
Clinical Trial Results
SEPTEMBER 1, 2024
Rasmussen_Laust Download Disclosures: TBD
American College of Cardiology
SEPTEMBER 1, 2024
Asundexian was associated with a higher incidence of stroke or systemic embolism, but less major bleeding, compared with apixaban among patients with atrial fibrillation (AFib) who were at high risk for stroke, based on findings from the OCEANIC-AF trial presented at ESC Congress 2024 in London and simultaneously published in The New England Journal of Medicine.
The American Journal of Cardiology
SEPTEMBER 1, 2024
Publication date: Available online 31 August 2024 Source: The American Journal of Cardiology Author(s): Ahmad Al-Abdouh, Dealla Samadi, Fares Sukhon, Mohammed Mhanna, Ahmad Jabri, Laith Alhuneafat, Taqwa Alabduh, Anas Bizanti, Luai Madanat, Mohammad Alqarqaz, Timir K Paul, Amartya Kundu
Expert insights. Personalized for you.
137 
Let's personalize your content